<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Oritavancin: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Oritavancin: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Oritavancin: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="96544" href="/d/html/96544.html" rel="external">see "Oritavancin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F25872800"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Kimyrsa;</li>
<li>Orbactiv</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F25562765"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Glycopeptide</li></ul></div>
<div class="block doa drugH1Div" id="F25855960"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2fae4cfb-934a-4756-86bc-073fe437156b">Endocarditis, treatment, step-down therapy in patients who inject drugs</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endocarditis, treatment, step-down therapy in patients who inject drugs (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Not first-line treatment; based on expert opinion. Reserve use for patients who inject drugs who had clinical improvement with IV treatment for <i>S. aureus</i> infection but cannot complete IV standard of care therapy and are unable to absorb oral antibiotics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36043414']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36043414'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>1.2 g once weekly for a total duration, including initial IV therapy, of 6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36043414']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36043414'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5fe294fd-4626-4e48-9579-84675accedc8">Skin and soft tissue infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infection (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Reserve for patients with or at risk for methicillin-resistant <i>S. aureus </i>infection who cannot receive preferred agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Spelman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Spelman.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV</b>: 1.2 g as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24897083','lexi-content-ref-25294250']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24897083','lexi-content-ref-25294250'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990273"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">CrCl ≥30 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &lt;30 mL/minute: There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">ESRD requiring hemodialysis: There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied); not removed by hemodialysis.</p></div>
<div class="block doha drugH1Div" id="F50987502"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate hepatic impairment (Child-Pugh class A or B): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe hepatic impairment (Child-Pugh class C): There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).</p></div>
<div class="block doe drugH1Div" id="F25855961"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F26188910"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral edema (&lt;2%), tachycardia (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Cellulitis (1%), erythema multiforme (&lt;2%), pruritus (&lt;2%), skin rash (&lt;2%), urticaria (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperuricemia (&lt;2%), hypoglycemia (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (4%), nausea (10%), vomiting (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (&lt;2%), eosinophilia (&lt;2%), positive direct Coombs' test (≤10%), positive indirect Coombs' test (≤10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (3%), increased serum aspartate aminotransferase (2%), increased total serum bilirubin (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema (&lt;2%), hypersensitivity angiitis (&lt;2%), hypersensitivity reaction (&lt;2%; including severe hypersensitivity reactions)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Abscess (subcutaneous and limb; 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Erythema at injection site (&lt;2%), induration at injection site (&lt;2%), injection-site phlebitis (3%), injection-site pruritus (2%), injection-site reaction (2%), rash at injection site (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (3%), headache (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myalgia (&lt;2%), osteomyelitis (&lt;2%), tenosynovitis (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm (&lt;2%), wheezing (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: <i>Clostridioides difficile</i>-associated diarrhea</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Infusion-related reaction</p></div>
<div class="block coi drugH1Div" id="F25562768"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to oritavancin or any component of the formulation; use of intravenous unfractionated heparin for 120 hours (5 days) after oritavancin administration (oritavancin falsely elevates aPTT for up to 120 hours (5 days) after administration).</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F25855944"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Serious hypersensitivity reactions, including anaphylaxis, have been reported (median onset in studies ~1.2 days). If an acute reaction occurs, discontinue infusion immediately and institute appropriate supportive care (median resolution ~2.4 days). Inquire about previous hypersensitivity reactions to glycopeptides; carefully monitor patients with a history of glycopeptide allergy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infusion reactions: Infusion related reactions (pruritus, urticaria, rash, flushing of the upper body) have been reported; reactions characterized by chest pain, back pain, chills, and tremor also have occurred. If reactions occur, consider slowing or interrupting infusion.</p>
<p style="text-indent:-2em;margin-left:4em;">• Osteomyelitis: In clinical trials, more cases of osteomyelitis were noted in patients treated with oritavancin. Monitor for signs and symptoms of osteomyelitis and institute appropriate alternate antibacterial therapy if warranted.</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Use may result in fungal or bacterial superinfection, including <i>Clostridioides</i>
<i>difficile</i> (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Product interchangeability: Oritavancin is available as 2 different products (Kimyrsa or Orbactiv) supplied in different strengths and with different preparation and administration directions; use extra precaution to ensure directions are followed correctly for desired product.</p></div>
<div class="block foc drugH1Div" id="F25872801"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Orbactiv: 400 mg (1 ea, 3 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous, as diphosphate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Kimyrsa: 1200 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous, as diphosphate [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Orbactiv: 400 mg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F25872799"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F26116582"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Kimyrsa Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1200 mg (per each): $6,217.73</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Orbactiv Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mg (per each): $1,392.97</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F25855965"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Oritavancin is available as 2 different products (Kimyrsa or Orbactiv) supplied in different strengths and with different preparation and administration directions; use extra precaution to ensure directions are followed correctly for desired product.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> If infusion-related reaction (pruritus, urticaria, flushing, rash) occurs, consider slowing or interrupting infusion.</p>
<p style="text-indent:-2em;margin-left:4em;">Kimyrsa: Infuse over 1 hour. If a common IV line is being used to administer other drugs in addition to oritavancin, the line should be flushed before and after each infusion with D5W or NS.</p>
<p style="text-indent:-2em;margin-left:4em;">Orbactiv: Infuse over 3 hours. If a common IV line is being used to administer other drugs in addition to oritavancin, the line should be flushed before and after each infusion with D5W.</p></div>
<div class="block use drugH1Div" id="F25562767"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Skin and soft tissue infection:</b> Treatment of adult patients with skin and soft tissue infections caused by susceptible isolates of the following gram-positive microorganisms: <i>Staphylococcus aureus</i> (including methicillin-susceptible and methicillin-resistant isolates); <i>Streptococcus pyogenes; Streptococcus agalactiae; Streptococcus dysgalactiae,</i>
<i>Streptococcus anginosus</i> group (including <i>S. anginosus, S. intermedius, S. constellatus</i>); and <i>Enterococcus faecalis</i> (vancomycin-susceptible isolates only)</p></div>
<div class="block off-label drugH1Div" id="F58692809"><span class="drugH1">Use: Off-Label: Adult</span><p>Endocarditis, treatment, step-down therapy in patients who inject drugs</p></div>
<div class="block cyt drugH1Div" id="F25590641"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F25590638"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Anticoagulants: Oritavancin may diminish the therapeutic effect of Anticoagulants. Specifically, oritavancin may artificially increase the results of laboratory tests commonly used to monitor anticoagulant effectiveness, which could lead to incorrect decisions to decrease anticoagulant doses. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparin: Oritavancin may diminish the therapeutic effect of Heparin. Specifically, oritavancin may artificially increase the results of laboratory tests commonly used to monitor IV heparin effectiveness, which could lead to incorrect decisions to decrease heparin doses. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Oritavancin may increase the serum concentration of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F25855941"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events were not observed in animal reproduction studies.</p></div>
<div class="block brc drugH1Div" id="F25855943"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if oritavancin is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F25855967"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Baseline serum urea nitrogen, serum creatinine, and LFTs (AST, ALT, bilirubin). Monitor patients for any kind of infusion-related reactions (pruritus, urticaria, flushing, rash), hypersensitivity reactions (especially in patients with reported glycopeptide allergy) and signs and symptoms of osteomyelitis.</p></div>
<div class="block pha drugH1Div" id="F25855951"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Oritavancin is a lipoglycopeptide with concentration-dependent bactericidal activity. It inhibits cell wall biosynthesis by inhibiting the polymerization step by binding to stem peptides of peptidoglycan precursors, by inhibiting crosslinking by binding to bridging segments, and by disrupting bacterial membrane integrity, leading to cell death.</p></div>
<div class="block phk drugH1Div" id="F25855953"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: ~87.6 L</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 85%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Not metabolized</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~245 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces and urine as unchanged drug (less than 1% and 5% in feces and urine, respectively, over two weeks postadministration)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F45783854"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Orbactiv | Tenkasi</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Tenkasi</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Tenkasi</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Tenkasi</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Orbactiv</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Tenkasi</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Tenkasi</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Tenkasi</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Tenkasi</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Kimyrsa</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-36043414">
<a name="36043414"></a>Baddour LM, Weimer MB, Wurcel AG, et al; American Heart Association Rheumatic Fever, Endocarditis and Kawasaki Disease Committee of the Council on Lifelong Congenital Heart Disease and Heart Health in the Young; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; and Council on Peripheral Vascular Disease. Management of infective endocarditis in people who inject drugs: a scientific statement from the American Heart Association. <i>Circulation</i>. 2022;146(14):e187-e201. doi:10.1161/CIR.0000000000001090<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oritavancin-drug-information/abstract-text/36043414/pubmed" id="36043414" target="_blank">36043414</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24897083">
<a name="24897083"></a>Corey GR, Kablier H, Mehra P, et al; SOLO I Investigators. Single-dose oritavancin in the treatment of acute bacterial skin infections. <i>N Engl J Med</i>. 2014;370(23):2180-2190.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oritavancin-drug-information/abstract-text/24897083/pubmed" id="24897083" target="_blank">24897083</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25294250">
<a name="25294250"></a>Corey GR, Good S, Jiang H, et al; SOLO II investigators. Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study. <i>Clin Infect Dis</i>. 2015;60(2):254-262. doi:10.1093/cid/ciu778<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oritavancin-drug-information/abstract-text/25294250/pubmed" id="25294250" target="_blank">25294250</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21537018">
<a name="21537018"></a>Dunbar LM, Milata J, McClure T, Wasilewski MM; SIMPLIFI Study Team. Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial. <i>Antimicrob Agents Chemother</i>. 2011;55(7):3476-3484.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oritavancin-drug-information/abstract-text/21537018/pubmed" id="21537018" target="_blank">21537018</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23261897">
<a name="23261897"></a>Karaoui LR, El-Lababidi R, Chahine EB. Oritavancin: an investigational lipoglycopeptide antibiotic. <i>Am J Health Syst Pharm</i>. 2013;70(1):23-33.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oritavancin-drug-information/abstract-text/23261897/pubmed" id="23261897" target="_blank">23261897</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Melinta.1">
<a name="Melinta.1"></a>Kimyrsa (oritavancin) [prescribing information]. Lincolnshire, IL: Melinta Therapeutics LLC; July 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Melinta.2">
<a name="Melinta.2"></a>Orbactiv (oritavancin) [prescribing information]. Lincolnshire, IL: Melinta Therapeutics LLC; January 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Spelman.1">
<a name="Spelman.1"></a>Spelman D, Baddour LM. Acute cellulitis and erysipelas in adults: Treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 17, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22431851">
<a name="22431851"></a>Zhanel GG, Schweizer F, Karlowsky JA. Oritavancin: mechanism of action. <i>Clin Infect Dis</i>. 2012;54(suppl 3):S214-S219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oritavancin-drug-information/abstract-text/22431851/pubmed" id="22431851" target="_blank">22431851</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 96543 Version 132.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
